Clinical Trial Update: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating cabergoline for treatment of corticotroph pituitary tumors in Cushing's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corticotroph Adenoma
• Cushing Disease

Drugs mentioned

• Dostinex (cabergoline) (cabergoline)

Snippet

Sponsor: Seth Gordhandas Sunderdas Medical College | Conditions: Cushing's Disease, Corticotroph Adenoma | Phase 3 | Status: COMPLETED